Biofrontera Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative dermatological therapies, with a particular emphasis on skin cancer treatments. The company's flagship product, Ameluz, is a leading therapy for actinic keratosis, supported by a sophisticated photodynamic therapy system that significantly improves patient outcomes. With a robust pipeline aimed at expanding its product offerings and global market presence, Biofrontera is strategically positioned to capitalize on the increasing demand for effective skin cancer solutions and to forge partnerships that will enhance its competitive standing in the healthcare sector.
| Revenue (TTM) | $46.17M |
| Gross Profit (TTM) | $36.59M |
| EBITDA | $-5.97M |
| Operating Margin | -4.37% |
| Return on Equity | -988.00% |
| Return on Assets | -17.40% |
| Revenue/Share (TTM) | $3.92 |
| Book Value | $0.42 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 32.90% |
| Shares Outstanding | 0 |
| Float | $11.84M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Volatility is currently contracting
Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera's photodynamic therapy platform
WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026.
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BFRIW and any ticker you trade — then tracks every position and per-strategy win rate.
